Expert Speaker Faculty

Take a look at the esteemed speaker faculty for the 7th Genome Editing Therapeutics Summit.

Innovative Biotech Experts
Large Pharma Leaders

Innovative Biotech Experts

Devyn Smith, Chief Executive Officer of Arbor Biotechnologies, discussing next-generation genome editing platforms and therapeutic innovation at the 7th Genome Editing Therapeutics Summit 2026

Devyn Smith

Chief Executive Officer
Arbor Biotechnologies
Chad Torgerson, Principal Scientist Arbor Biotechnologies - Expert Speaker at the 7th Genome Editing Therapeutics Summit 2026

Chad Torgerson

Principal Scientist
Arbor Biotechnologies
Lauren Young, Senior Director of Genomics and Computational Biology at Beam Therapeutics, discussing genomic analysis, off-target assessment and genome editing safety at the 7th Genome Editing Therapeutics Summit 2026

Lauren Young

Senior Director - Genomics & Computational Biology
Beam Therapeutics
Lalit Kumar, Senior Director of Clinical Bioanalytics and Translational Science at Beam Therapeutics, presenting clinical bioanalysis strategies for genome editing programs at the 7th Genome Editing Therapeutics Summit 2026

Lalit Kumar

Senior Director, Clinical Bioanalytics & Translational Science
Beam Therapeutics
Gopi Shanker, Chief Scientific Officer at Beam Therapeutics, discussing clinical translation of genome editing technologies and therapeutic development at the 7th Genome Editing Therapeutics Summit 2026

Gopi Shanker

Chief Scientific Officer
Beam Therapeutics
Bin Wu, Founder and CEO of Cytodigm, presenting innovative delivery technologies to expand genome editing applications beyond traditional targets at the 7th Genome Editing Therapeutics Summit 2026

Bin Wu

Founder & Chief Executive Officer
Cytodigm

Jenny Xie

In vivo Gene Editing Lead
Editas Medicine
Wenning Qin, Senior Vice President of Research at eGenesis, discussing engineered cellular technologies and novel genome editing applications at the 7th Genome Editing Therapeutics Summit 2026

Wenning Qin

Senior Vice President - Research
eGenesis
Kelan Hlavaty, Senior Director of Technical Operations at eGenesis, presenting manufacturing scalability and operational strategies for genome editing therapeutics at the 7th Genome Editing Therapeutics Summit 2026

Kelan Hlavaty

Senior Director, Technical Operations
eGenesis
Xiao Yang, Senior Principal Scientist at Epicrispr Biotechnologies, presenting advances in epigenome editing and programmable gene regulation technologies at the 7th Genome Editing Therapeutics Summit 2026

XIAO Yang

Senior Principal Scientist
Epicripsr Biotechnologies
Howard Wu, Co-Founder and Chief Scientific Officer of Full Circles Therapeutics, discussing emerging genome editing approaches and therapeutic innovation at the 7th Genome Editing Therapeutics Summit 2026

Howard Wu

Co-Founder & Chief Scientific Officer
Full Circles Therapeutics
Birgit Schultes, Chief Scientific Officer at Intellia Therapeutics, discussing in vivo genome editing development and clinical advancement strategies at the 7th Genome Editing Therapeutics Summit 2026

Birgit Schultes

Chief Scientific Officer
Intellia Therapeutics
Jesse Owens, Chief Scientific Advisor at Komo Biosciences, presenting innovative genome editing technologies and translational development strategies at the 7th Genome Editing Therapeutics Summit 2026

Jesse Owens

Chief Scientific Advisor
Komo Biosciences
Alan Brooks, Senior Vice President of Research at Metagenomi Therapeutics, discussing translational genome editing programs and pathways toward clinical success at the 7th Genome Editing Therapeutics Summit 2026

Alan Brooks

Senior Vice President, Research
Metagenomi Therapeutics
Cindy Liu, Director of Molecular Analytical Development at Prime Medicine, presenting analytical development and quality strategies for genome editing therapies at the 7th Genome Editing Therapeutics Summit 2026

Cindy Liu

Director, Molecular Analytical Development
Prime Medicine
Sarah Denny, PhD, Sr. Director at Scribe Therapeutics discussing X-Editor for Therapeutic-Grade In Vivo Editing with DeepXE, a Predictive Model for Guide Potency at the 7th Genome Editing Therapeutics Summit 2026

Sarah Denny

Senior Director
Scribe Therapeutics

Large Pharma Leaders

Ishani Dasgupta, Senior Scientist at AbbVie, discussing genome editing safety, immunogenicity assessment and therapeutic development strategies at the 7th Genome Editing Therapeutics Summit (Formerly the CRISPR 2.0 Summit)

Ishani Dasgupta

Senior Scientist
AbbVie
Matthew Laurie, Senior Scientist at Bristol Myers Squibb, presenting insights on off-target analysis, genomic integrity and genome editing safety evaluation at the 7th Genome Editing Therapeutics Summit 2026

Matthew Laurie

Senior Scientist
Bristol Myers Squibb
John Moore, Senior Director of Translational Gene Editing at Eli Lilly, discussing translational genome editing research and clinical development pathways at the 7th Genome Editing Therapeutics Summit 2026

John Moore

Senior Director - Translational Gene Editing
Eli Lilly
Wei-Chiang Chen, Associate Director at Sanofi, sharing strategies for advancing genome editing therapeutics from preclinical research to clinical application at the 7th Genome Editing Therapeutics Summit 2026

Wei-chiang chen

Associate Director
Sanofi
7th Genome Editing Therapeutics Summit 2026 Event Image

Explore the Agenda

See exactly which delivery, manufacturing and regulatory sessions are relevant to your genome editing program.

View Presentations & Speakers
7th Genome Editing Therapeutics Summit 2026 Event Image

Partner With Us

Put your solutions in front of the genome editing decision-makers actively looking for them.

Explore Sponsorship Options
7th Genome Editing Therapeutics Summit 2026 Event Image

Join Genome Editing Experts

Connect with the R&D, clinical and regulatory leaders driving genome editing therapeutics forward.

Register Now